oxycodone has been researched along with Cachexia in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ishida, T; Kawakami, J; Naito, T; Ohnishi, K; Tashiro, M | 1 |
Ishida, T; Kawakami, J; Naito, T; Sato, H | 1 |
Kagawa, Y; Kawakami, J; Naito, T; Ohnishi, K; Tashiro, M; Yamamoto, K | 1 |
1 trial(s) available for oxycodone and Cachexia
Article | Year |
---|---|
Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
Topics: Aged; Analgesics, Opioid; Cachexia; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Humans; Male; Middle Aged; Morphinans; Neoplasms; Oxycodone; Oxymorphone; Pain | 2013 |
2 other study(ies) available for oxycodone and Cachexia
Article | Year |
---|---|
Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients.
Topics: Aged; Analgesics, Opioid; Cachexia; Cytochrome P-450 CYP3A; Delayed-Action Preparations; Delirium; Depression; Disorders of Excessive Somnolence; Female; Humans; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Neoplasms; Oxycodone; Tumor Necrosis Factor-alpha | 2016 |
Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients.
Topics: Acute-Phase Proteins; Aged; Analgesics, Opioid; Asian People; Cachexia; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Neoplasms; Oxycodone; Pain; Pain Measurement; Serum Albumin; Tablets | 2012 |